Stock Analiz3M Co. MMM
Medical/Dental Instruments · data as of November 13, 2026
3M Co. (MMM) is a healthcare company listed in the US with a market value of about $94.9B. In the twelve months to September 30, 2026 it had revenue of $25.2B and net income of $3.5B, a net margin of 14.0%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 27.4, a price to free cash flow of 35.5, 5-year revenue growth of -5% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 52% below the current price.
Score: 1.4 / 5
Checks passed
- Profit margin improving
- ROE above 15%
- Positive free cash flow
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.2B | $24.9B | $24.6B | $24.6B | $26.2B | $35.4B | $32.2B | $32.1B | $32.8B | $31.7B | $30.1B |
| Net income | $3.5B | $3.2B | $4.2B | -$7.0B | $5.8B | $5.9B | $5.4B | $4.5B | $5.3B | $4.9B | $5.0B |
| Free cash flow | $2.7B | $1.4B | $638M | $5.1B | $3.8B | $5.9B | $6.6B | $5.4B | $4.9B | $4.9B | $5.2B |
| EPS (diluted) | $6.71 | $6.00 | $7.55 | $-12.63 | $10.18 | $10.12 | $9.36 | $7.72 | $8.89 | $7.93 | $8.16 |
| Net margin | 14.0% | 13.0% | 17.0% | -28.4% | 22.1% | 16.8% | 16.9% | 14.1% | 16.3% | 15.3% | 16.8% |
| ROIC | — | 19.8% | 23.0% | -40.2% | 13.2% | 18.2% | 17.7% | 15.9% | 22.6% | 19.4% | 23.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 17 analysts is $193.43, 5% above the current price; targets range from $125.00 to $230.00; the consensus rating is “Buy”; expected EPS is $9.13 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is 3M’s P/E ratio?
About 27.4, based on the last twelve months of diluted earnings per share (forward P/E about 19.8).
Is 3M stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 52% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does 3M pay a dividend?
Yes. The dividend yield is about 1.65%, and it has paid dividends for 10 years in our data.
Is 3M a good stock to buy?
We do not give buy or sell advice. 3M scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.